朗格汉斯细胞组织细胞增生症 (Langerhans cell histiocytosis,LCH) 是一种由骨髓细胞肿瘤性增殖引起的罕见疾病，多见于儿童。LCH临床表现多样，以骨骼受累最常见。该文报道了一例儿童颅眶沟通LCH，影像学检查结果提示患儿右侧眉弓处类圆形穿凿样骨质破坏，通过手术切除病灶，送组织病理学检查明确诊断，同时选择通过3D打印聚醚醚酮(polyetheretherketone,PEEK)材料修补颅眶缺损部位，PEEK材料匹配度高、安全性好，改善患儿预后，提升患儿生存质量。
Langerhans cell histiocyte (LCH) is a rare disease caused by the tumor-like proliferation of bone marrow cells, which is mostly seen in children. Its clinical manifestations can be diverse, in which the skeletal system is most involved. This paper reports a case of LCH in cranio-orbital communication of a child. The imaging results suggest that there is a round chisel damage at the patient’s right brow ridge. In terms of definitive diagnosis and treatment, this patient underwent surgical resection and histopathological examination. 3D-printed polyether-ether-ketone (PEEK) material was selected to repair the cranio-orbital defect. The material can achieve better biocompatibility, while 3D-printing technique allows higher matching degree, both help to improve the prognosis and quality of life of the patient.
青光眼作为首位不可逆性致盲眼病给患者、家庭和社会带来重大损害和沉重的经济负担。在视觉2020计划收官之年，中国青光眼防治工作已获得较好成绩，但仍面临严峻挑战。在未来，中国青光眼防治工作将以《2020中国青光眼指南》为蓝本，有望依托人工智能技术，实现对青光眼患者的高效、便捷、准确的筛查和诊断；以患者个体特征、疾病特点和社会环境为立足点，采取个性化和精准化治疗；结合慢病管理的全生命周期概念，实现对患者的终身监测和指导。提高我国青光眼诊治水平，减少青光眼致残致盲。
Glaucoma is a leading cause of irreversible blindness in the world. It brings great damage and heavy economic burden to patients, their families and society. Under the Vision 2020 initiative, great progress has been achieved in the glaucoma prevention and treatment in China, but there are still severe challenges ahead. In the future, the Guideline for Glaucoma Care in China (2020) will act as the blueprint of the prevention and treatment of glaucoma in China. Efficient, convenient and accurate screening and diagnosis of glaucoma will be achieved relying on the artificial intelligence technology. Personalized and precision therapy will be carried out based on individual and disease characteristics and social environment. Also, lifelong monitoring and guidance of patients will be realized in the context of the whole life cycle of chronic diseases. Glaucoma care will be further improved to continuously reduce vision impairment and blindness caused by glaucoma.
青光眼作为首位不可逆性致盲眼病给患者、家庭和社会带来重大损害和沉重的经济负担。在视觉2020计划收官之年，中国青光眼防治工作已获得较好成绩，但仍面临严峻挑战。在未来，中国青光眼防治工作将以《2020中国青光眼指南》为蓝本，有望依托人工智能技术，实现对青光眼患者的高效、便捷、准确的筛查和诊断；以患者个体特征、疾病特点和社会环境为立足点，采取个性化和精准化治疗；结合慢病管理的全生命周期概念，实现对患者的终身监测和指导。提高我国青光眼诊治水平，减少青光眼致残致盲。
Glaucoma is a leading cause of irreversible blindness in the world. It brings great damage and heavy economic burden to patients, their families and society. Under the Vision 2020 initiative, great progress has been achieved in the glaucoma prevention and treatment in China, but there are still severe challenges ahead. In the future, the Guideline for Glaucoma Care in China (2020) will act as the blueprint of the prevention and treatment of glaucoma in China. Efficient, convenient and accurate screening and diagnosis of glaucoma will be achieved relying on the artificial intelligence technology. Personalized and precision therapy will be carried out based on individual and disease characteristics and social environment. Also, lifelong monitoring and guidance of patients will be realized in the context of the whole life cycle of chronic diseases. Glaucoma care will be further improved to continuously reduce vision impairment and blindness caused by glaucoma.
